DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance.

Autor:	Conway K; Department of Epidemiology, University of North Carolina, Chapel Hill, NC.; Department of Dermatology, University of North Carolina, Chapel Hill, NC.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Edmiston SN; Department of Dermatology, University of North Carolina, Chapel Hill, NC.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC., Vondras A; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Reiner A; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Corcoran DL; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC., Shen R; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Parrish EA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Hao H; Department of Dermatology, University of North Carolina, Chapel Hill, NC., Lin L; Department of Dermatology, University of North Carolina, Chapel Hill, NC., Kenney JM; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Ilelaboye G; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Kostrzewa CE; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Kuan PF; Department of Applied Mathematics and Statistics, State University of New York, Stony Brook, NY., Busam KJ; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Lezcano C; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Lee TK; British Columbia Cancer Research Center, Vancouver, BC, Canada., Hernando E; Grossman School of Medicine, New York University, New York, NY., Googe PB; Department of Dermatology, University of North Carolina, Chapel Hill, NC.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC., Ollila DW; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC., Moschos S; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC., Gorlov I; Department of Medicine, Baylor Medical Center, Houston, TX., Amos CI; Department of Medicine, Baylor Medical Center, Houston, TX., Ernstoff MS; ImmunoOncology Branch, National Cancer Institute, Rockville, MD., Cust AE; The Daffodil Centre, The University of Sydney, a Joint Venture with Cancer Council NSW, Sydney, NSW, Australia.; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia.; Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia., Wilmott JS; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia., Scolyer RA; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia., Mann GJ; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia.; John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia., Vergara IA; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia., Ko J; Cleveland Clinic Foundation, Cleveland, OH., Rees JR; Department of Epidemiology, Dartmouth Medical School, Lebanon, NH., Yan S; Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH., Nagore E; Instituto Valenciano de Oncologia, Valencia, Spain.; Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain., Bosenberg M; Department of Pathology, Yale University, New Haven, CT., Rothberg BG; Leonard Miller School of Medicine, University of Miami, Miami, FL., Osman I; Grossman School of Medicine, New York University, New York, NY., Lee JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Saenger Y; Columbia University Medical School, New York, NY.; Albert Einstein School of Medicine, New York, NY., Bogner P; Departments of Pathology and Dermatology, Roswell Park Comprehensive Cancer Center, Buffalo, NY., Thompson CL; Case Western Reserve University, Cleveland, OH.; Penn State University, Hershey, PA., Gerstenblith M; Case Western Reserve University, Cleveland, OH., Holmen SL; Department of Surgery, University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT., Funchain P; Stanford University, Palo Alto, CA., Brunsgaard E; Department of Dermatology, Rush University Medical Center, Chicago, IL., Depcik-Smith ND; GPA Laboratories, Sonic Healthcare, Greensboro, NC., Luo L; Department of Internal Medicine and the UNM Comprehensive Cancer Center, Albuquerque, NM., Boyce T; Department of Internal Medicine and the UNM Comprehensive Cancer Center, Albuquerque, NM., Orlow I; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Begg CB; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Berwick M; Department of Internal Medicine and the UNM Comprehensive Cancer Center, Albuquerque, NM., Thomas NE; Department of Dermatology, University of North Carolina, Chapel Hill, NC.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Jazyk:	angličtina
Zdroj:	JCO precision oncology [JCO Precis Oncol] 2024 Nov; Vol. 8, pp. e2400375. Date of Electronic Publication: 2024 Nov 07.
DOI:	10.1200/PO-24-00375
Abstrakt:	Purpose: Patients with stage II and III cutaneous primary melanoma vary considerably in their risk of melanoma-related death. We explore the ability of methylation profiling to distinguish primary melanoma methylation classes and their associations with clinicopathologic characteristics and survival. Materials and Methods: InterMEL is a retrospective case-control study that assembled primary cutaneous melanomas from American Joint Committee on Cancer (AJCC) 8th edition stage II and III patients diagnosed between 1998 and 2015 in the United States and Australia. Cases are patients who died of melanoma within 5 years from original diagnosis. Controls survived longer than 5 years without evidence of melanoma recurrence or relapse. Methylation classes, distinguished by consensus clustering of 850K methylation data, were evaluated for their clinicopathologic characteristics, 5-year survival status, and differentially methylated gene sets. Results: Among 422 InterMEL melanomas, consensus clustering revealed three primary melanoma methylation classes (MethylClasses): a CpG island methylator phenotype (CIMP) class, an intermediate methylation (IM) class, and a low methylation (LM) class. CIMP and IM were associated with higher AJCC stage (both P = .002), Breslow thickness (CIMP P = .002; IM P = .006), and mitotic index (both P < .001) compared with LM, while IM had higher N stage than CIMP ( P = .01) and LM ( P = .007). CIMP and IM had a 2-fold higher likelihood of 5-year death from melanoma than LM (CIMP odds ratio [OR], 2.16 [95% CI, 1.18 to 3.96]; IM OR, 2.00 [95% CI, 1.12 to 3.58]) in a multivariable model adjusted for age, sex, log Breslow thickness, ulceration, mitotic index, and N stage. Despite more extensive CpG island hypermethylation in CIMP, CIMP and IM shared similar patterns of differential methylation and gene set enrichment compared with LM. Conclusion: Melanoma MethylClasses may provide clinical value in predicting 5-year death from melanoma among patients with primary melanoma independent of other clinicopathologic factors.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu